CR20200320A - Once-daily formulation of hidrosmin - Google Patents
Once-daily formulation of hidrosminInfo
- Publication number
- CR20200320A CR20200320A CR20200320A CR20200320A CR20200320A CR 20200320 A CR20200320 A CR 20200320A CR 20200320 A CR20200320 A CR 20200320A CR 20200320 A CR20200320 A CR 20200320A CR 20200320 A CR20200320 A CR 20200320A
- Authority
- CR
- Costa Rica
- Prior art keywords
- hidrosmin
- once
- daily formulation
- formulation
- hemorrhoids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>The present invention relates to a formulation comprising hidrosmin characterized by a modified release rate suitable for once-daily administration.The use of said composition in the prevention or treatment of a disease selected from chronic venous insufficiency, varicose veins, hemorrhoids, edema,metabolic syndrome,non-alcoholic fatty liver disease and diabetic nephropathy is also provided.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382877 | 2017-12-21 | ||
| PCT/EP2018/086053 WO2019122051A1 (en) | 2017-12-21 | 2018-12-20 | Once-daily formulation of hidrosmin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200320A true CR20200320A (en) | 2020-12-14 |
Family
ID=60923332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200320A CR20200320A (en) | 2017-12-21 | 2018-12-20 | Once-daily formulation of hidrosmin |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3727345A1 (en) |
| AR (1) | AR113993A1 (en) |
| BR (1) | BR112020012437A2 (en) |
| CL (1) | CL2020001697A1 (en) |
| CO (1) | CO2020008721A2 (en) |
| CR (1) | CR20200320A (en) |
| EA (1) | EA202091535A1 (en) |
| EC (1) | ECSP20041796A (en) |
| MX (1) | MX2020006505A (en) |
| NI (1) | NI202000049A (en) |
| PE (1) | PE20210458A1 (en) |
| PH (1) | PH12020550926A1 (en) |
| SG (1) | SG11202005652YA (en) |
| UY (1) | UY38026A (en) |
| WO (1) | WO2019122051A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130202705A1 (en) | 2010-05-11 | 2013-08-08 | Cima Labs Inc. | Alcohol-resistant formulations |
| CN116869951A (en) | 2015-10-09 | 2023-10-13 | 拜尔健康护理有限责任公司 | Modified release formulation of naproxen sodium |
-
2018
- 2018-12-19 AR ARP180103740A patent/AR113993A1/en unknown
- 2018-12-20 BR BR112020012437-0A patent/BR112020012437A2/en unknown
- 2018-12-20 MX MX2020006505A patent/MX2020006505A/en unknown
- 2018-12-20 WO PCT/EP2018/086053 patent/WO2019122051A1/en active Search and Examination
- 2018-12-20 EP EP18826649.8A patent/EP3727345A1/en active Pending
- 2018-12-20 PE PE2020000781A patent/PE20210458A1/en unknown
- 2018-12-20 CR CR20200320A patent/CR20200320A/en unknown
- 2018-12-20 UY UY0001038026A patent/UY38026A/en not_active Application Discontinuation
- 2018-12-20 EA EA202091535A patent/EA202091535A1/en unknown
- 2018-12-20 SG SG11202005652YA patent/SG11202005652YA/en unknown
-
2020
- 2020-06-17 PH PH12020550926A patent/PH12020550926A1/en unknown
- 2020-06-19 NI NI202000049A patent/NI202000049A/en unknown
- 2020-06-19 CL CL2020001697A patent/CL2020001697A1/en unknown
- 2020-07-15 CO CONC2020/0008721A patent/CO2020008721A2/en unknown
- 2020-07-20 EC ECSENADI202041796A patent/ECSP20041796A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020012437A2 (en) | 2020-11-24 |
| UY38026A (en) | 2019-07-31 |
| EP3727345A1 (en) | 2020-10-28 |
| ECSP20041796A (en) | 2020-10-30 |
| PH12020550926A1 (en) | 2021-05-31 |
| WO2019122051A1 (en) | 2019-06-27 |
| AR113993A1 (en) | 2020-07-08 |
| SG11202005652YA (en) | 2020-07-29 |
| NI202000049A (en) | 2020-11-24 |
| MX2020006505A (en) | 2020-09-17 |
| EA202091535A1 (en) | 2020-09-11 |
| CL2020001697A1 (en) | 2020-11-27 |
| PE20210458A1 (en) | 2021-03-08 |
| CO2020008721A2 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012595A (en) | Topical pharmaceutical compositions. | |
| PH12019501131A1 (en) | Composition for treating hyperlipidemia comprising oxytomodulin derivative | |
| PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
| MX2018005193A (en) | Dual function proteins and pharmaceutical composition comprising same. | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| DOP2018000027A (en) | INHIBITOR OF MUTED DEHYDROGENASE ISOCITRATE IDH1 R132H | |
| MX2013003635A (en) | N-heteroaryl compounds. | |
| MX2017005861A (en) | Methods to target transcriptional control at super-enhancer regions. | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| EA033298B1 (en) | Tesofensine and metoprolol combination formulation | |
| NZ600695A (en) | Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency | |
| AU2017261919A1 (en) | Fat and medical uses thereof | |
| PH12020550926A1 (en) | Once-daily formulation of hidrosmin | |
| MX2019014988A (en) | Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus. | |
| WO2014007549A3 (en) | Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same | |
| MX2018006921A (en) | Methods and compositions for treating gastric ulcers. | |
| MX2017013481A (en) | Rivastigmine-containing sustained-release pharmaceutical composition. | |
| MX2019000717A (en) | Compositions comprising a polysaccharide matrix for the controlled release of active ingredients. | |
| MX2018015203A (en) | Sclerosing solution. | |
| JP2016513647A5 (en) | ||
| EA201700390A1 (en) | VASCULAR AGENT AS OIL | |
| MX2017000717A (en) | Combination of adapalene and benzoyl peroxide for the treatment of severe acne. |